Charles Schwab
LYEL icon

Charles Schwab’s Lyell Immunopharma LYEL Stock Holding History

Charles Schwab’s Portfolio LYEL Stock Details LYEL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.51M Buy
107,570
+21,599
+25% +$391K ﹤0.01% 2877
2026
Q1 		$1.72M Buy
85,971
+548
+0.6% +$12.8K ﹤0.01% 2753
2025
Q4 		$2.63M Buy
85,423
+5,913
+7% +$132K ﹤0.01% 2682
2025
Q3 		$1.29M Buy
79,510
+18,007
+29% +$206K ﹤0.01% 2871
2025
Q2 		$544K Sell
61,503
-18,731
-23% -$171K ﹤0.01% 3112
2025
Q1 		$863K Sell
80,234
-2,055
-2% -$25.2K ﹤0.01% 2889
2024
Q4 		$1.05M Buy
82,289
+24,920
+43% +$494K ﹤0.01% 2897
2024
Q3 		$1.58M Sell
57,369
-7,513
-12% -$221K ﹤0.01% 2775
2024
Q2 		$1.88M Buy
64,882
+911
+1% +$43.4K ﹤0.01% 2726
2024
Q1 		$2.85M Buy
63,971
+628
+1% +$26.9K ﹤0.01% 2487
2023
Q4 		$2.46M Buy
63,343
+807
+1% +$29.1K ﹤0.01% 2550
2023
Q3 		$1.84M Buy
62,536
+4,936
+9% +$234K ﹤0.01% 2623
2023
Q2 		$3.66M Buy
57,600
+626
+1% +$34.6K ﹤0.01% 2358
2023
Q1 		$2.69M Buy
56,974
+331
+0.6% +$17.7K ﹤0.01% 2443
2022
Q4 		$3.93M Buy
56,643
+1,037
+2% +$103K ﹤0.01% 2339
2022
Q3 		$8.15M Buy
55,606
+31,146
+127% +$4.22M ﹤0.01% 1951
2022
Q2 		$3.19M Buy
24,460
+1,803
+8% +$184K ﹤0.01% 2389
2022
Q1 		$2.29M Buy
22,657
+14,097
+165% +$1.71M ﹤0.01% 2601
2021
Q4 		$1.33M Buy
8,560
+247
+3% +$55.1K ﹤0.01% 2808
2021
Q3 		$2.46M Buy
+8,313
New +$2.49M ﹤0.01% 2655

Other funds holding LYEL

AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
GP
GSK plc London $602M AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
OPL
Orland Properties Ltd Road Town, Tortola, British Virgin Islands $202M AUM 2.79% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $417M AUM 22.81% 1-Year Est. Return
FCMV
Foresite Capital Management V Larkspur, California $362M AUM 386.37% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return

Charles Schwab's LYEL Position: Q2 2026 in Review

Charles Schwab increased its Lyell Immunopharma (LYEL) stake by 25% in Q2 2026, buying an estimated $391K and bringing the position to 107,570 shares worth $1.51M. The position accounts for ﹤0.01% of the portfolio, ranked #2877.

Charles Schwab first reported a position in LYEL in Q3 2021 and has held it in 20 quarters since. The position peaked at $8.15M in Q3 2022. 87 funds tracked by Wall St. Rank hold LYEL as of Q2 2026.

  • Charles Schwab held 107,570 shares of Lyell Immunopharma worth $1.51M as of Q2 2026.
  • Charles Schwab bought 21,599 Lyell Immunopharma shares in Q2 2026, an estimated $391K.
  • Lyell Immunopharma made up ﹤0.01% of Charles Schwab's portfolio in Q2 2026, its #2877 holding.
  • Charles Schwab first reported a position in Lyell Immunopharma in Q3 2021 and has held it in 20 quarters since.
  • Charles Schwab's Lyell Immunopharma position peaked at $8.15M in Q3 2022.
  • 87 funds tracked by Wall St. Rank held Lyell Immunopharma as of Q2 2026.

Based on Charles Schwab's 13F filing for Q2 2026, filed 14 Aug 2026.